SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Access Pharma CEO Interview: Updates and Outlook
SNY
|
|
|
+9.79%
in
73 days
<> Corporate Profile has posted a <font> video interview on YouTube </font> with the President and CEO of Access Pharma (ACCP.ob), Jeffrey B. Davis, which summarizes the compelling investment opportunity represented by his Company. Mr. Davis provides an overview of Access Pharma, explaining that it is not a development-stage company because MuGard has already received marketing clearance by the FDA in the U.S. along with similar approvals worldwide and is in the early stages of its global commercial launch. Furthermore, the Company expects multiple catalysts before year-end which have t...
|
FDA Calendar Updates: POZN, AZN, SNY, CEPH, APPY, CYTR
SNY
|
|
|
+17.61%
in
60 days
(closed on 08/29/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
Access Pharma (OTC:ACCP): Low Valuation, Big Potential
SNY
|
|
|
+0.24%
in
55 days
(closed on 06/30/09)
With shares of Cell Therapeutics (NASDAQ:CTIC) staging the most astonishing comeback I have ever witnessed while rising from 8 cents at the time of <font> my original article in early February </font> to as high as $1.85 during intraday trading today and closing at $1.27 – I went in search of another out-of-favor name in the cancer biotech space. <> Access Pharma (OTC:ACCP) is an emerging bio-pharma company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to an FDA approved treatment for a side effect of some cancer treatmen...
|
Unilife: Making Syringes Safer, Relocating to U.S.
SNY
|
|
|
+5.63%
in
36 days
(closed on 05/06/09)
For the first time since its public listing in 2002, Unilife Medical Solutions (Australia: UNI.AX) (U.S. ADR: UNIFF.PK) posted a net profit which came in at $11M for the six-month period ending 12/31/08. Unilife posted a 43% increase in revenue to $2.7M, compared to the year-ago period and net income was driven by $23.4M in other income (largely accounted for by a major licensing deal for the Company's pre-filled syringe). The Company ended the year with $10.9M in cash/equivalents and total liabilities of $7.4M ($3.2M current, $4.2M long-term). <> <>http://biomedreport...
|
Updated Clinical Trial and FDA Decision Calendars
SNY
|
|
|
+1.06%
in
11 days
(closed on 03/31/09)
Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars. <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through 3/20/09. The FDA Calendar includes the following information: company name, ticker, decision date, and descrip...
|
From the Blogosphere
Big Pharma & Biotech – Industry Outlook
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Big Pharma & Biotech – Zacks Analyst Interviews
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Big Pharma and Biotech – Industry Outlook
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Lower Q3 Loss for Regeneron – Analyst Blog
|
|
|
Regeneron Pharmaceuticals Inc. (REGN) reported a third-quarter net loss of $1.015 million, or 1 cent per share, which was much better than the Zacks Consensus Estimate of a loss of 23 cents. The company suffered a loss of $19.084 million or 24 cents in the year-ago quarter.
The narrower loss reflected the increased contract research and development revenues from its collaborations with Sanofi-Aventis (SNY) and Bayer HealthCare, coupled with a milestone payment from Bayer.
Total revenues for the quarter came in at $117.45 million from $65.58 million, up 79%. Total revenues consisted of contrac...
|
Micromet Misses Estimates – Analyst Blog
|
|
|
Micromet’s (MITI) third-quarter loss per share came in at 22 cents, well below the Zacks Consensus Estimate of 14 cents and a loss of 15 cents in the prior-year period. The company reported revenues of $4 million, compared to $7 million in the third quarter of 2008. Micromet records revenues primarily in the form of reimbursements of expenses incurred by the company under different collaborative agreements. We believe current investor focus is more on the developments of the company’s portfolio rather than the financials. <>Operating expenses during the quarter increased 28% year over year...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Confidence Restored?
- CONFIDENCE RESTORED?
Have we all of the sudden seen a dramatic improvement in confidence? The action over the last 2 days (the best 2 day gain since 1...
|
More Resources
|
About SanofiAventis
- Answers.com
